LA NEUROTOXCITE DU PACLITAXEL ; DE L’EXPLORATION CLINIQUE A LA PRISE EN CHARGE

Abstract

aclitaxel, a commonly used chemotherapeutic agent in the treatment of various cancers, can induce significant neurotoxicity impacting patients' quality of life. Our study, descriptive and retrospective, included 30 patients with diverse cancers treated with paclitaxel at the Medical Oncology Departments of KHENCHELA and BOUSAADA. Our results indicate that the majority of patients experienced neurological symptoms, notably numbness (96.7%), tingling (96.7%), and burning sensations in the extremities (100%). Symptom severity varied, with most patients reporting Grade 2 or Grade 1 symptoms. Additionally, 26.7% of patients reported memory disturbances, and 30% had difficulties with fine motor tasks in their hands. These symptoms notably impacted quality of life, with approximately a quarter of patients facing challenges in performing daily activities. Most patients used medications or methods to alleviate symptoms, although only 6.7% consulted a neurologist for specialized management. Therapeutic adjustments were infrequent, indicating relatively stable management of neurological symptoms. Our study underscores the importance of monitoring and proactive management of paclitaxel-induced neurological symptoms. An integrated approach involving specialized consultations and personalized management strategies is crucial to improve patient quality of life while maintaining treatment efficacy.